Related Experiment Videos
Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling
1Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287-2101, USA.
Cancer Research
|June 19, 2001
Summary
Gene expression profiling revealed significant differences between prostate cancer and benign prostatic hyperplasia (BPH). This study identifies key genes, like hepsin, offering potential diagnostic and therapeutic markers for prostate malignancy.
Area of Science:
- Molecular Biology
- Oncology
- Genomics
Background:
- Prostate malignancy's biology and molecular underpinnings are not fully understood.
- Distinguishing between benign and malignant prostate cell growth is crucial.
Purpose of the Study:
- To identify fundamental molecular differences between benign prostatic hyperplasia (BPH) and prostate cancer.
- To discover novel molecular markers for prostate cancer diagnosis and treatment.
Main Methods:
- Gene expression profiling of 16 prostate cancer and 9 BPH specimens using cDNA microarrays (6500 genes).
- RNA extraction from enriched benign and malignant epithelial cell regions.
- Normalized gene expression comparison against a common reference.
Main Results:
- Distinct gene expression patterns clearly differentiate prostate cancer from BPH.
- Identified 210 genes with statistically significant expression differences.
- Included novel differentially expressed genes, such as hepsin (transmembrane serine protease).
Conclusions:
- Significant and widespread gene expression differences exist between benign and malignant prostate tissues.
- Gene expression analysis can elucidate molecular mechanisms of prostate cancer.
- Identified genes may serve as valuable diagnostic, prognostic, and therapeutic markers.